Business Club, February 10th, the first trading day after the Spring Festival February 7，Shuanglong shares that have been suspended for nearly two months issued an announcement name，Company and its wholly -owned subsidiary Wanzai Shuanglong intends to purchase 100%of the shares of Jinbao Pharmaceutical in the way of issuing shares and payment of cash，The preliminary negotiated transaction price is 1.08 billion yuan。Industry insiders think，This merger is a microcosm of the M & A "Economic Reference (Weibo)" that has been set off in the pharmaceutical industry.，In order to solve problems such as overcapacity of pharmaceutical companies，The Ministry of Industry and Information Technology and other relevant government departments will issue relevant documents in the near future，Support the merger and reorganization of several industries including the pharmaceutical industry。
 
Actually，Except Shuanglong shares，Kang Enbei, a listed company in another pharmaceutical My stake betting appindustry, also issued an announcement，Company stocks continue to suspend trading from February 7, 2014。Kang Enbei further disclosed，The major asset reorganization of the company's plan is the acquisition of equity assets of a domestic pharmaceutical company。The company intends to divide the steps to use cash and (or) non -public issuance of shares to purchase assets to achieve the acquisition of the equity of the pharmaceutical company，The purpose is to seize the opportunity for the integration of the domestic pharmaceutical industry at this stage，Accelerate the implementation of the company's plant medicine development strategy，Further enhances the company's core business competitiveness and business performance。
 
Earlier，Another pharmaceutical industry listed company in A shares Nanjing Pharmaceutical issued an announcement，Strategic investment with Union Bo Zi obtained the principle of the Ministry of Commerce。According to this strategic investment plan，Nanjing Pharmaceut，12%of the company's total share capital after the issuance，It is expected to raise 1.06 billion yuan。From the perspective of the industry，After being approved by the Ministry of Commerce，This fixed increase plan is likely to be approved。Nanjing Pharmaceutical Express，Through cooperation，Nanjing Pharmaceutical Introduction International Advanced Technology and Innovation C formal format，Promote the upgrade of local traditional industries。and the industry insiders pointed out，This is the first time that foreign pharmaceutical distribution enterprises have entered my country's pharmaceutical circulation industry，Can quickly seize the opportunity of the industry。
 
"Economic Reference News" reporter preliminary statistics discovery，2013，Medical listed companies' mergers and acquisitions are significantly accelerated: Stake Sports Bettingincluding China Resources Sanjiu acquisition of Shandong Lingqinghua Weiye Pharmaceutical; Renhe Pharmaceutical acquisition of East Konson Pharmaceutical; Shanghai Rice acquisition of Pharmaceuticals; Lepu Medical acquisition of new handsome pharmaceuticals ; Watson Biological acquisition of Daan Pharmaceutical; uniquely intended to acquire hospitals such as Pengxi; Xinhua Medical acquisition 90%equity of Yuanyue Pharmaceutical Machine，There are more than 20 mergers and acquisitions cases。
 
Xu Lingni, a researcher at the pharmaceutical industry research center of China Investment Consultant Industry Research Center, pointed out，The pharmaceutical industry has become a hot spot for capital chase，The reason is that there is still huge development space in my country's pharmaceutical industry。my country's pharmaceutical industry currently accounts for only 3%，The gap between 15%and 20%compared to developed countries is far away。& ldquo; The valuation of the current capital market to the pharmaceutical industry is not consistent，The valuation of the generic drug market will gradually decrease，and biopharmaceutical、Chinese medicine valuation is not too high，Just waiting for the further release of the later development of the industry，It will become a hot spot for investment。Especially Chinese medicine，With the establishment and improvement of the traditional Chinese medicine system，Market space will also gradually expand。& rdquo; Xu Lingni said，Shuanglong Co., Ltd. acquired Jinbao Pharmaceutical is just a beginning。
 
An industry insider broke the substantial essence of the drug production enterprise and purchased the tide of the tide & mdash; & mdash; & mdash; & ldquo;。He told the "Economic Reference News" reporter，At present, the State Food and Drug Administration is relatively strict with registered approval.，It's too difficult to get a pharmaceutical Stake Sports Bettingnumber，But the approved number of drugs is illegal。So，Many companies pass the mergers and acquisitions，Get more high -quality pharmaceutical numbers for easy drugs。Announcement of Shuanglong Shares，At present, Jinbao Pharmaceutical has 66 pharmaceutical production approval number，Among them, 35 products are included in the national medical insurance directory，35 varieties are included in the "National Basic Drug Catalog"，31 drugs are included in the OTC variety catalog (23 categories of type A varieties，8 types B varieties)。
 
Wind statistics show，At present, 118 listed pharmaceutical companies released the 2013 annual report。Calculate the upper limit of the year -on -year increase of net profit，23 listed companies' net profit fell year -on -year，Among them, Northeast Pharmaceuticals fell 1211%、Fourth Ring Biological decline 795%; net profit of 90 listed companies increased year -on -year，Among them, Kinpu Titanium industry increased by 2899%、Jiaying Pharmaceutical increased by 1749%。Calculate the lower limit of the year -on -year increase of net profit，35 listed companies' net profit fell year -on -year，Among them, Northeast Pharmaceuticals Fall 1581%、Fourth Ring Biological decline of 795%; the net profit of 67 listed companies increased year -on -year，Among them, Kinpu Titanium industry increased by 2899%、Jiaying Pharmaceutical increased by 1710%。
 
And these performances have changed sharply，Mostly related to the M & A and reorganization items。For example，Jiaying Pharmaceutical Company's performance has changed so much，The merger of Hunan Sands Pharmaceutical Co., Ltd., which is integrated with the company, is related to the combined company under the same control。
 
& ldquo; The merger is still the theme of the medical industry this year。Benefiting from industry integration and reform dividends，Medical Device、Medical services and pharmaceutical manufacturing will usher in the peak period for mergers and acquisitions stake online sports bettingintegration。& rdquo; The above -mentioned insiders revealed to the "Economic Reference News"，In order to solve problems such as overcapacity of pharmaceutical companies，The Ministry of Industry and Information Technology and other relevant government departments will issue relevant documents in the near future，Support the merger and reorganization of several industries including the pharmaceutical industry，Its purpose is to remove excess capacity in the pharmaceutical industry。